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PSY6
CONTRIBUTIONS OF THE HUNTER OUTCOME SURVEY (HOS) TO
ADVANCING UNDERSTANDING OF HUNTER SYNDROME
Muenzer J1, Beck M2, Giugliani R3, Hernberg-Ståhl E4, Wraith JE5
1University of North Carolina, Chapel Hill, NC, USA, 2University of Mainz, Mainz, Germany, 
3Hospital de Clinicas/UFRGS, Porto Alegre, RS, Brazil, 4Shire Human Genetic Therapies, 
Danderyd, Sweden, 5Royal Manchester Children’s Hospital, Manchester, UK
OBJECTIVES: To review how the Hunter Outcome Survey (HOS), a physician-driven, 
multinational, observational survey supported by Shire HGT, has helped advance 
the understanding and management of Hunter syndrome—a rare, X-linked disorder
of glycosaminoglycan (GAG) metabolism caused by deﬁ ciency of the enzyme iduro-
nate-2-sulfatase. METHODS: HOS was established in 2005 to help understand the 
natural history of Hunter syndrome and the long-term safety and effectiveness of 
enzyme replacement therapy (ERT) with idursulfase. Data such as demographics,
signs/symptoms, investigations, developmental milestones and laboratory test data
are collected for patients with a conﬁ rmed diagnosis. Three working groups
(Natural History, Cardiac and CNS) have been established to further data collection/
interpretation in the respective ﬁ elds. RESULTS: As of January 2009, 98 clinics across
23 countries have enrolled 642 patients. The ﬁ rst peer-reviewed paper, published in 
2008, reported that the median ages of onset of symptoms and diagnosis were 1.5
and 3.5 years, respectively; the average height of Hunter children was normal up
to approximately 9 years of age, following which it fell below the third percentile 
(Wraith et al., 2008). Other important ﬁ ndings include: by 6 years of age half 
of patients showed cardiovascular abnormalities (Wraith et al., 2007); the majority 
of patients developed airway involvement in childhood (Burton et al., 2008); and 
prior to diagnosis, the most common clinical symptoms were characteristic facial 
features, enlarged liver and spleen, hernia and otitis (Beck et al., 2007). CONCLU-
SIONS: In the short time HOS has been running, it has provided important real-
world data on Hunter syndrome. Data analyses have identiﬁ ed the need for early 
diagnosis, to enable institution of appropriate therapeutic management. Through 
ongoing collaboration between participating physicians and working groups, HOS
will continue to expand the evidence base of knowledge around Hunter Syndrome
and be a valuable tool to evaluate the effectiveness of ERT and help optimize patient
care.
PSY7
DISEASE FLARES AMONG PATIENTS WITH CROHN’S DISEASE
Waters HC1, Bolge SC2, Freedman D2, Piech CT1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Consumer Health Sciences 
International, Princeton, NJ, USA
OBJECTIVES: Crohn’s disease (CD) causes inﬂ ammation in the lining of the small
or large intestine and is characterized by disease ﬂ ares. This study quantiﬁ ed the
incidence of disease ﬂ ares among adult patients with CD, and assessed the impact 
of ﬂ ares on resource utilization. METHODS: Cross-sectional data were collected via 
the Inﬂ ammatory Bowel Disease (IBD) Study Project during Q3 2008. Study partici-
pants were recruited from an Internet panel and were reported to have IBD as diag-
nosed by a physician. All survey respondents were aged q18 years. RESULTS: A total
of 500 patients with CD completed the survey. Overall, 32.0% of all CD patients
reported one or more ﬂ ares per week, while an additional 26.8% reported one or
more ﬂ ares per month. Patients reporting one or more ﬂ ares per week were signiﬁ -
cantly younger (42.2 years) and had CD for shorter lengths of time (11.7 years) than 
patients with less frequent disease ﬂ ares. The former were more likely to classify their
disease as moderate to severe, uncontrolled, and more bothersome. The majority of 
disease ﬂ ares lasted less than one week and were of moderate severity. Patients expe-
riencing more frequent disease ﬂ ares were signiﬁ cantly more likely to have been hos-
pitalized (28.8% vs. 6.5%), have longer lengths of stay (2.2 days vs. 0.9 days), visited 
the emergency room (40.6% vs. 6.5%), and visited their gastroenterologist (60.6% 
vs. 32.3%) in the past six months as a result of their CD. These patients were also 
more likely to have higher degrees of work productivity loss. CONCLUSIONS: The 
majority of patients with CD experience disease ﬂ ares at least monthly, and the more
frequent the ﬂ ares, the greater the resource utilization and disruption to work life. 
Treatments that adequately control disease ﬂ ares may result in cost offsets and should
be examined.
PSY8
IMPORTANCE OF ROUTINE URINE DRUG TESTING IN THE CHRONIC
PAIN PATIENT POPULATION
Couto JE1, Leider HL2, Romney M1, Goldfarb NI1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Ameritox, Ltd, Baltimore, MD, USA
OBJECTIVES: To describe rates of inappropriate utilization, abuse, and diversion in
a population of patients who were prescribed chronic opioids, as measured by urine
drug testing (UDT) in the clinical setting. A secondary objective is to inform providers, 
payors and policy-makers about the importance of routine monitoring of patients on
chronic opioids. METHODS: A retrospective analysis was conducted of a database 
containing results from all urine drug tests conducted between January 2006 and 
September 2008, by Ameritox, Ltd. using their RxGuardian(sm) monitoring algo-
rithms, for patients whose physicians ordered the test in order to screen for non-
compliance. RESULTS: Data from over 800,000 patient test samples obtained from 
over 500,000 unique patients showed that 75% of patients were deemed “noncompli-
ant” with their prescribed pain regimen. Of patients determined to be noncompliant; 
39% were found to not have the prescribed opioid present, 29% had non-prescribed
opioid medications present, 27% had a drug level higher than expected, 15% had a
drug level lower than expected, and 11% had illicit drugs detected in their urine. 
CONCLUSIONS: The high observed rate of noncompliance in this patient population
implies high rates of non-adherence, overuse, and diversion of prescribed opioid 
medications. Previous research has compared direct per-patient costs of insured opioid 
abusers versus non-abusers, and found signiﬁ cantly higher health care costs for opioid
abusers. These higher costs have been attributed to increased utilization of services
and prescription products, as well as more frequent comorbidities. Utilizing a UDT
that can not only detect the presence of other non-prescribed and illicit drugs, but also
is sensitive enough to determine whether the patient is adherent to their current 
regimen provides a powerful tool for clinicians seeking to identify and decrease non-
compliance, overuse, and diversion of controlled substances in their practice.
PSY9
USING UTILIZATION RECORDS TO ESTIMATE THE BURDEN OF
OBESITY IN ADULTS LIVING IN ONTARIO
Tarride JE, Haq M, O’Reilly D, Xie F, Bowen JM, Goeree R
McMaster University, Hamilton, ON, Canada
OBJECTIVES: To present an overview of the burden of obesity in adults by using the 
richness of a Canadian population health survey linked to Ontario administrative 
databases. METHODS: The records of all Ontarians who participated in the Canadian
Community Health Survey (CCHS), cycle 1.1 (2000/2001) and provided consent to 
data linkage with administrative databases were linked to the Ontario Health Insur-
ance Program (OHIP) claims database and the Discharge Abstract Database (DAD) 
In-Patient and Day Procedure database. Prevalence of obesity in this adult population 
was documented using the body mass index (BMI) calculated by Statistics Canada for 
adults aged 20–64 years of age. Socio-demographics (e.g. age, gender, education),
medical characteristics (e.g. comorbidities), health related quality of life (Health Utility 
Index 3), self-reported health and one-year physician and hospitalization costs were
described per BMI category (i.e. underweight, normal weight, overweight and obese).
RESULTS: More than 50% of adult participants were either overweight or obese in
2000/2001. When classiﬁ ed by BMI categories, obese individuals were more likely to
be older, males, have more comorbidities, a lower quality of life and higher one-year
medical costs. A Generalized Linear Model (GLM) indicated that age, gender, obese, 
being inactive and smoker increased signiﬁ cantly the total costs. Compared to normal
weight adults, being underweight or obese were also positive predictors of costs. 
Health-related quality of life, income or being overweight had no impact on costs.
CONCLUSIONS: These results suggest that the burden of obesity in Ontario is 
considerable.
PSY10
PREVALENCE OF METABOLIC SYNDROME AND DIFFERENCES IN
HEALTH HABITS AMONG SUFFERERS AMONG U.S. ETHNIC GROUPS
Kannan H, Wagner S, Bolge SC
Consumer Health Sciences International, Princeton, NJ, USA
OBJECTIVES: To quantify prevalence of metabolic syndrome in U.S. ethnic groups
and determine ethnic differences in health habits among sufferers. METHODS: Data 
were obtained from the 2008 U.S. National Health and Wellness Survey (NHWS), a
national, patient-reported, Internet-based study of health care attitudes, behaviors, 
health status, and outcomes of adults aged 18. Metabolic syndrome was deﬁ ned as
experiencing at least three of the following: type 2 diabetes, high cholesterol, hyperten-
sion, BMI q 30. Smoking, regular exercise (16 times/month), visiting a physician in
the past six months, and insurance status were assessed. Frequency weights based on 
age, race and gender were used to calculate prevalence estimates. Logistic regression
was used to determined effects of ethnicity on metabolic syndrome and health habits 
among sufferers while adjusting for other demographics. Analyses were limited to
self-identiﬁ ed white (reference group), black, Hispanic and Asian respondents. 
RESULTS: Of the 61,016 respondents, 9.0% (projected 16.7M; 7.8%) experienced 
metabolic syndrome. Prevalence varied across ethnic groups: White  12.8 M, 8.4%; 
Black  19.5 M, 7.9%; Hispanic  1.6 M, 5.8%; Asian  0.3 M, 3.2%). Adjusting 
for other demographics, blacks were more likely (OR  1.35, p  0.01), Asians less
likely (OR  0.58, p  0.01), and Hispanics equally as likely to have metabolic syn-
drome as whites. There were signiﬁ cant (p  0.05) ethnic differences in selected health 
habits among sufferers after adjusting for other demographics. Speciﬁ cally, Hispanics 
were 0.69 times as likely to be current smokers and 0.69 times as likely to visit a 
primary care physician as whites, and blacks were 0.64 times as likely to have health 
insurance as whites. CONCLUSIONS: Complex conditions such as metabolic syn-
drome present new challenges in ethnic health and health care research due to varia-
tions in the prevalence and risk factors by ethnic groups. Among metabolic syndrome
sufferers, ethnic disparities in health habits, physician visits, and insurance status may 
lead to differential outcomes by ethnic group.
PSY11
ESTIMATION OF CAUSAL EFFECTS OF PHYSICAL ACTIVITY ON
OBESITY BY A RECURSIVE BIVARIATE PROBIT MODEL
Kawatkar AA, Nichol MB
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: The study objective was to quantify the causal effect of physical activity
(PA) on obesity controlling for unobservable factors causing bias. METHODS: Data 
from the MEPS’s Household Component (2006), a nationally representative survey of 
the U.S. civilian non-institutionalized population, were used. Analysis accounted for 
the survey’s clusters, strata and sampling weights. Treatment variable was a binary
indicator if an individual spent half hour or more in moderate to vigorous physical
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activity at least three times a week. Obesity (OB) was deﬁ ned by a binary indicator if 
body mass index was greater than 30. The structural parameter, average treatment 
effect (ATE) was deﬁ ned as the impact of PA on obesity, if individuals are randomly 
assigned to PA. The second parameter average treatment in the treated (ATET) mea-
sured the impact of PA on obesity amongst those who became physically active, rather
than for the population as a whole. To control for the unobservable factors affecting 
PA, we speciﬁ ed a recursive bivariate probit model. To avoid identiﬁ cation based on
functional form, instruments added were presence of any limitations, and injury. 
Covariates included age, gender, race, ethnicity, geographical and metropolitan area 
location, smoking status, comorbidities and perceived physical and mental health.
RESULTS: Based on naïve probit model, the probability of obesity, evaluated at the 
means of the data, was 0.099 lower amongst those who were physically active (p 
0.001). Effect of selection bias was positive and signiﬁ cant (rho  0.55 p  0.001). 
Based on the recursive probit model, ATE was a 27.7% decrease (95% CI 0.279 to 
0.275) while ATET was a 38.8% decrease (95% CI 0.391 to 0.385) in probability
of obesity amongst those who were physically active. CONCLUSIONS: Unobservable 
heterogeneity may be masking the true effect of physical activity on obesity. Account-
ing for this bias conﬁ rms a signiﬁ cant protective effect of physical activity against the 
likelihood of obesity.
PSY12
TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PATIENTS
WITH MYELODYSPLASTIC SYNDROME OR SEVERE ANEMIA: DATA
FROM MULTI-CENTER CLINICAL PRACTICES
Raptis A1, Duh MS2, Wang ST2, Dial E2, Fanourgiakis I1, Fortner B3, Paley C4, Mody-Patel N4, 
Corral M4, Scott J5
1University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, 2Analysis Group, Inc., 
Boston, MA, USA, 3P4 Healthcare, Lakeland, TN, USA, 4Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA, 5P4 Healthcare, Ellicott City, MD, USA
OBJECTIVES: Patients with myelodysplastic syndrome (MDS) or severe anemia
requiring repeated transfusions of red blood cells (RBCs) risk developing transfusional
iron overload (TIO), which can cause organ damage and reduce survival. Iron chela-
tion therapy (ICT) has been shown to improve survival and quality of life in patients 
with TIO; however, ICT utilization in clinical practices is not well understood. 
METHODS: The medical records of patients diagnosed with MDS or severe anemia 
q6 months before data extraction, aged q 21 years at their diagnosis, received q1 RBC 
transfusion were reviewed. ICT-eligibility was deﬁ ned as q20 units of RBCs transfused 
or q2 serum ferritin (SF) tests q1000 mcg/L. Study endpoint was ICT-treatment rate 
among ICT-eligible patients with lower-risk MDS [IPSS (low or intermediate-1); WHO
(RA, RARS, RCMD, RCMD-RS or 5q); FAB (RA or RARS)]. Characteristics and
survival of treated and untreated groups were described. RESULTS: Medical records
data for 283 patients were extracted. Among 78 ICT-eligible patients with lower-risk 
MDS, only 32 (41%) received ICT. At ICT-initiation, treated patients received on 
average 13.3 transfusions (27.6 units) and mean ﬁ rst SF near-ICT-initiation was twice
the recommended level at 1949 mcg/L. Median overall survival for all ICT-eligible 
patients was signiﬁ cantly longer for those ICT-treated than untreated (8.7 versus 4.7 
years, log-rank p  0.02; multivariate hazards ratio  0.372, p  0.03). CONCLU-
SIONS: This observational study ﬁ nds only 41% of ICT-eligible patients with lower-
risk MDS received ICT in clinical practice, and their treatment was initiated later than 
recommended. Among all ICT-eligible patients, those who received ICT had a signiﬁ -
cantly better overall survival than untreated patients.
PSY13
FREQUENCY AND BOTHERSOMENESS OF SIDE EFFECTS IN PAIN 
PATIENTS TAKING OXYCODONE IMMEDIATE RELEASE: IMPACT ON
PRESCRIPTION AND OVER-THE-COUNTER MEDICATION USE
Anastassopoulos K1, Chow W2, Ackerman SJ3, Tapia CI3, Benson C2, Kim M2
1Covance Market Access Services, Inc, Gaithersburg, MD, USA, 2Ortho-McNeil Janssen 
Scientiﬁ c Affairs, LLC, Raritan, NJ, USA, 3Covance Market Access Services, Inc, San Diego, 
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OBJECTIVES: Oxycodone immediate release, alone or in combination (oxycodone), 
is widely used to treat pain. However, oxycodone is often associated with bothersome
side effects, which may lead to increased medical resource use, including prescription 
and over-the-counter (OTC) medications. The objective of this ﬁ rst analysis was to 
assess the frequency and bothersomeness of side effects and other medication use
among patients taking oxycodone. METHODS: An online survey was completed by
a nationwide convenience sample of patients currently taking oxycodone for non-
malignant pain. Detailed data on patient experience with oxycodone were collected. 
A minimum sample size of 600 was determined to ensure reasonably accurate esti-
mates around the frequency of side effects and medical resource utilization. RESULTS:
Among the 601 respondents [mean age of 45 years (range 18–86), 85.0% Caucasian,
69.1% female], almost half, 45.6%, were taking oxycodone for back/neck pain, 
16.8% for osteoarthritis/rheumatoid arthritis, 14.3% for pain due to injury/trauma, 
10.5% for recent surgery, 7.2% for ﬁ bromyalgia, and 5.7% for neuropathic pain. The
mean daily dose was 16.5 mg (range 2.5–200). Overall, 83.5% were bothered by side
effects with 29.9% being moderately/extremely bothered. Over half, 53.1%, were 
bothered by constipation, almost one-third, 31.3%, by nausea, 27.6% by pruritus, 
and 14.8% by vomiting, among others. A signiﬁ cantly higher proportion of respon-
dents bothered by side effects reported use of prescription (13.1% vs. 0%; p  0.001)
or OTC (20.5% vs. 9.1%; p  0.007) medications to manage those side effects, com-
pared to respondents not bothered by side effects. CONCLUSIONS: The majority of 
survey respondents experienced side effects of oxycodone, some of which led to the 
use of prescription and OTC medications. These results point to the potential beneﬁ ts, 
both humanistic and economic, of better-tolerated pain medications. Further analyses 
of this data will assess the health status, pain intensity, and other resource utilization
among oxycodone users.
PSY14
TOLERABILITY OF INTRAVENOUSLY ADMINISTERED IMMUNE
GLOBULIN IN THE HOME SETTING
Tankersley MA
Accredo Health, Inc, Memphis, TN, USA
OBJECTIVES: Patients with primary immune deﬁ ciencies and many neurological
disorders are frequently treated with immune globulin, administered intravenously or 
subcutaneously. The aim of this study was to evaluate tolerability of intravenously 
administered immune globulin products in patients in the home setting. METHODS:
A retrospective, longitudinal cohort analysis of patients (18 years and older) provided 
intravenous immunoglobulin (IVIG) using data from the Accredo Therapeutics elec-
tronic medical record was conducted. Inclusion criterion was infusion of at least one 
dose of IVIG during the study period. Patients were followed from July 1, 2007 to 
June 28, 2008. Three components to estimate tolerability were evaluated. The ﬁ rst 
was aggregate adverse drug event rate. The second was infusion completion rate (ICR),
calculated by dividing the number of successful infusions by the number of attempted
infusions. The third measure was a managed therapy completion rate (MTCR-A) for 
patients that had an identiﬁ ed ADE and were still managed to completion of therapy.
RESULTS: The sample size for review was 33,065 doses of IVIG dispensed during the 
study period. The results based upon the three measures of tolerability were: 1) an 
ADE rate of 2.35% (95% CI: 1.79%–2.93%) based on 778 reported adverse drug
events; 2) an infusion completion rate (ICR) of 99.74% (95% CI: 99.65%–99.82%);
and 3) a managed through completion of therapy (MTCR-A) of 88.6% (95% CI: 
80.8%–92.35%). Gender, age, diagnoses and BMI were also evaluated for their effect
upon tolerability of infusion. CONCLUSIONS: Intravenous administration of immune
globulin is an important alternative infusion option for patients. Patients can be well 
managed in the home on intravenously administered immunoglobulin. These ﬁ ndings 
contribute to previous research related to safety of administration of immunoglobulin 
in the home.
SYSTEMIC DISORDERS/CONDITIONS – Cost Studies
PSY15
THE IMPACT OF ADHERENCE ON THE COSTS AND BENEFITS OF
INTENSIVE LIFESTYLE MANAGEMENT (ILM) IN OVERWEIGHT AND 
OBESE PATIENTS AT HIGH RISK FOR TYPE-2 DIABETES MELLITUS
(T2DM)
Willis M1, Asseburg C1, He J2, Neslusan C2
1IHE – The Swedish Institute for Health Economics, Lund, Sweden, 2Johnson & Johnson
Pharmaceutical Services LLC, Raritan, NJ, USA
OBJECTIVES: The Diabetes Prevention Program (DPP) demonstrated that ILM 
improves lipid values, reduces blood pressure and reduces the risk of developing 
T2DM. Controversy over magnitude of whether these beneﬁ ts can be achieved cost-
effectively has diverted attention from questions about the generalizability of the
results. The high rate of treatment adherence in the DPP may not be reproducible in 
actual practice. The objective of this study was to assess the impact of treatment 
adherence to ILM on estimates of health beneﬁ ts and costs for a cohort of overweight
and obese patients at high risk of developing T2DM. METHODS: The IHE/JNJ
weight management model, a Markov-based, micro-simulation model that includes 
relevant co-morbidities and risk factors, was used to simulate the costs and health 
outcomes of ILM over 25 years for 500 cohorts of 1,000 hypothetical overweight and 
obese pre-T2DM patients. Efﬁ cacy and baseline population characteristics were taken 
primarily from the DPP. Costs for ILM and care associated micro- and macro-vascular 
complications and other co-morbidities as well as quality-of life data was obtained
from existing literature. Four scenarios were assessed: adherence as observed in the
DPP and reductions in the DPP adherence rate by 25%, 50%, and 75%. RESULTS:
In all, ILM resulted in 19.96 undiscounted life years (LYs), 18.03 undiscounted
quality-adjusted life years (QALYs), at a cost of $78,965, assuming DPP-like adher-
ence. Forty percent of the cohort ultimately developed T2DM. Reducing adherence 
by 25%, 50%, and 75% reduced LYs by 0.17, 0.29, and 0.40, QALYs by 0.36, 0.68, 
and 1.03, and increased costs by $2154, $4190, $6813, respectively. The rate of 
T2DM transition increased by 5, 10, and 15 percentage points, respectively. CON-
CLUSIONS: Patient adherence is an important driver of the beneﬁ ts and costs of ILM
and should be considered explicitly in cost-effectiveness estimates.
PSY16
A CANADIAN BASED PHARMACOECONOMIC ANALYSIS OF SELECTED
ANTICONVULSANTS, SNRIS AND TCAS IN TREATING NEUROPATHIC
PAIN
Iskedjian M, Walker J
PharmIdeas Research and Consulting Inc, Oakville, ON, Canada
OBJECTIVES: Neuropathic pain starts as or is caused by a primary lesion or dysfunc-
tion in the nervous system. It impacts use of health care resources and may incur
employment disruptions. The primary goal in managing neuropathic pain is to make 
it more tolerable. Three classes of atypical medications, anticonvulsants (ACs), sero-
